Professor, Uppsala University

Uppsala, Sverige
Joined September 2017
📢 GPCR Forum is back after Summer break ☀️ As the first Zoominar after the break, we are hosting @NourKahlous from @CarlssonLab at @uppsalauni on the 27th of August, 4 pm CET. As always, send a DM to receive the JOIN link or check the @GPCRForum mailing list.
5
2
9
538
We present a structure-based strategy for discovering small molecules targeting peptide-activated receptors. Applied to neurotensin receptors #GPCRs, it yielded anti-pain compounds rdcu.be/fwQ0Z To enable broader application of the strategy, we provide access to...1/x
1
2
3
238
Recent advances in #peptide-GPCR interactions are transforming drug discovery. This #Primer details experimental and computational approaches, from in silico peptide mining to modern biosensor assays, paving the way for novel therapeutics. nature.com/articles/s43586-0…
1
2
8
504
CarlssonLab retweeted
Great use of comparative genomics to engineer receptors! Stay tuned for our upcoming publication (fingers crossed) investing similar evolutionary hotspots for all human GPCR families.
1
4
267
Improving AlphaFold2 Performance in Virtual Screens Targeting GPCRs by Enhancing Binding-Site Conformational Sampling 1. The paper introduces AFsample2T, a targeted AlphaFold2 sampling strategy that boosts virtual screening performance for GPCRs by generating diverse binding-site conformations rather than relying on a single “best” structure. 2. Core idea: mask selected MSA columns only in the orthosteric-site region (extracellular-facing TM segments + part of EL2) to weaken local coevolution constraints and encourage alternative pocket geometries, while keeping the rest of the receptor well-constrained. 3. AFsample2T contrasts with global masking (AFsample2), which reduced binding-site accuracy for GPCRs here (AUC 0.38). Targeted masking preserved fold quality while improving pocket modeling, showing that “where to perturb” matters as much as “how much to perturb”. 4. The authors benchmarked 10 class A GPCRs using 61 curated experimental binding-site structures (from an initial pool of 119 PDB structures) and generated 1,000 models per receptor to quantify how often predicted pockets match experimental ones within 1–2 Å side-chain RMSD (symmetry-aware). 5. Moderate targeted masking improved binding-site accuracy: default AF2 AUC 0.54; adding dropout without masking AUC 0.57; targeted masking at 10–30% reached AUC ~0.59–0.61. Too much masking (50%) degraded secondary structure and collapsed performance (AUC 0.43). 6. The best-performing ensemble (AFsample2T) mixes 250 models each from 0%, 10%, 20%, and 30% masking (with dropout), yielding AUC 0.63 and capturing 73.8% of experimental binding sites at 1.5 Å RMSD vs 60.7% for AF2 (a 22% relative gain at that threshold). 7. A key mechanistic improvement is realistic binding-site plasticity. Median binding-site side-chain RMSF increased from 0.15 Å (AF2; overly rigid pockets) to 0.45 Å (AFsample2T), approaching experimental variability (median 0.58 Å). Backbone RMSF similarly moved from 0.10 Å (AF2) to 0.28 Å (AFsample2T), close to experiment (0.30 Å). 8. AFsample2T also mitigates a known docking issue: AF2 often predicts narrow/collapsed pockets. Across receptors, mean pocket volume increased (209 → 218 Å3) and the “top 1% most open” pockets expanded substantially (272 → 389 Å3), closer to experimental pockets (mean 256 Å3). This was especially relevant for μ-opioid receptor, where AF2 pockets were too collapsed. 9. Virtual screening evaluation used DOCK3.8 with ChEMBL actives (52–202 per receptor) and property-matched ZINC20 decoys, totaling extremely large-scale docking (reported as >240 trillion complexes scored). Rigid-receptor docking was used, making pocket microstates critical. 10. Ensemble screening + ligand-guided model selection is the practical win: while median enrichment of AF2-based models remained below experimental structures, the top 1% AFsample2T models improved early enrichment (mean aLogAUC top 1%: 10.8 → 12.9; mean EF1% top 1%: 7.5 → 9.6). In some targets (e.g., TAAR1, μ-opioid receptor), best AFsample2T models approached top experimental-structure performance. 11. The paper provides a workflow for prospective use: generate ≥250 AFsample2T models for the relevant receptor state, dock a ligand/decoy control set to compute enrichment, select ~top 1% models, manually inspect key interactions/poses, then proceed to large-library prospective screening. 12. Modeling receptor state is handled explicitly: inactive models use receptor sequence alone; active models are generated by cofolding receptor with heterotrimeric G protein sequences via AF2-Multimer, capturing hallmark TM6 movements and separating “state sampling” from “pocket microstate sampling”. 💻Code: github.com/wallnerlab/AFsamp… 📜Paper: doi.org/10.1021/acs.jcim.6c0… #AlphaFold2 #GPCR #VirtualScreening #Docking #StructureBasedDrugDesign #ComputationalChemistry #Bioinformatics #ProteinStructure #DrugDiscovery #MachineLearning
15
90
5,062
"AlphaFold3 fails to model receptor-ligand complexes for understudied targets" nature.com/articles/s41467-0…
5
41
2
256
19,086
CarlssonLab retweeted
Ultra-large virtual screening unveils potent agonists of the neuromodulatory orphan receptor GPR139 nature.com/articles/s41467-0…
4
21
3,611
CarlssonLab retweeted
Replying to @CarlssonLab
@CarlssonLab proves it: GPCR modeling only works with real collaboration—chemists, pharmacologists, modelers in sync. 🎧 Hear how it’s done: ecosystem.drgpcr.com/dr-gpcr… #DrGPCR #GPCR #TeamScience #DrugDesign
1
4
139
CarlssonLab retweeted
“Explain” is outdated. Can your model predict a GPCR response? @CarlssonLab at Uppsala builds models with the goal to guide real experiments. 🎧 ecosystem.drgpcr.com/dr-gpcr… #DrGPCR #GPCR #MolecularModeling #DrugDiscovery
1
3
262
CarlssonLab retweeted
Control duration, penetration & PK/PD separation. Plus: Jens Carlsson on predictive modeling + this week’s Premium sneak peek. Read & share ➤ bit.ly/3KVlL4m #DrGPCR #GPCR
1
2
268
CarlssonLab retweeted
Replying to @CarlssonLab
@CarlssonLab failed at the bench and found his calling in modeling. Now his lab predicts GPCR-ligand outcomes before they’re tested. 🎧 Hear his story: ecosystem.drgpcr.com/dr-gpcr… #DrGPCR #GPCR #CareerInScience #ComputationalBiology
2
6
189
CarlssonLab retweeted
Article: Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D2 Receptor #research supported by Knut and Alice Wallenberg Foundation #KAW100 #Parkinsons #Dopamine @CarlssonLab @ACSPublications tinyurl.com/ycxdkcum
1
2
486
AI meets rapid antiviral design. We used EvoBind to design a cyclic peptide HIV-1 inhibitor in a single shot to a novel interface, directly from sequence. Low micromolar activity, no toxicity, no structural data needed. biorxiv.org/content/10.1101/…
4
42
4
218
40,734
Glad to share our new article on the #hydrophobic #collapse of #PROTACs ! pubs.acs.org/doi/10.1021/acs…
2
11
693